Artepharm’s breakthrough ACT- Artequick - has been granted patents in 40 countries worldwide
Publisher： Artepharm Time：2017-02-23Browse：1152 font size：【large】【middle】【small】
Since its establishment, Artepharm has focused on innovating science and technology as well as strengthening management of intellectual property protection.That’s why it has developed a well-established intellectual property protection system. On June 17, 2015, the company’s ACT -Artequick- (Artemisinin and Piperaquine tablets) has been granted intellectual property right in the DR Congo. It is the fortieth country in the world where the drug has been successfully granted a patent.
All these successful grants help the company improve its intellectual property protection system, and effectively protect its main brand and core technology. Having a global approach to intellectual property protection remains a powerful weapon for the company to develop and compete in today’s international economic environment characterized by overwhelming globalization. It enables the company to achieve a sustainable and long-term global competitive advantage; hence stay leader in the area of antimalarial drugs.
Artequick is the innovative breakthrough drug of Artepharm. Its characteristics are high efficacy, quick action, safety and cost-effectiveness. It has been listed as the first-line and essential drug for the prevention and treatment of falciparum malaria by China’s Ministry of Health as well as one of the authorized selected antimalarial drugs for foreign aid by China’s Ministry of Commerce.
